The Joint Reconstruction Devices market is anticipated to grow from US$ 28.06 billion in 2024 to US$ 39.87 billion by 2031; the market is expected to register a CAGR of 5.3% from 2025 to 2031. The joint reconstruction devices market growth is attributed to the rising global prevalence of cancer, advancements in epigenetic technologies, and the expanding role of personalized medicine.

Joint reconstruction devices are medical implants and associated surgical instruments designed to restore function, reduce pain, and replace or repair damaged joints caused by arthritis, trauma, or degenerative conditions. The surge in 3D printing and additive manufacturing for patient-specific implants, expansion of AI and robotic-assisted systems for precision surgery, rise of regenerative biomaterials and biodegradable implants are expected to be major joint reconstruction devices market trends in the coming years.

The joint reconstruction devices market in North America is segmented into the US, Canada, and Mexico. The North America joint reconstruction devices market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The demand for joint reconstruction devices in the region is fueled by the rising prevalence of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and osteoporosis-largely driven by an aging population-has significantly increased the demand for joint replacement procedures.

The major factor that affected the joint reconstruction devices market in the US was the prevalence of arthritis-related conditions. Such illnesses alone have accounted for a staggering number of million people, who in response have raised the demand for reconstructive interventions. Based on the data provided by the Centers for Disease Control and Prevention (CDC), by 2022, approximately 18.9% of the adult population, that is more than 53 million individuals, has been affected by arthritis. The most common form of the disease, osteoarthritis (OA) affects 32.5 million adults, mainly seniors over 65 years. On the other hand, naturally, the country's rheumatoid arthritis (RA), an immune system disorder, impacts around 1.5 million individuals. Generally, these kinds of conditions appear as chronic joint pain, stiffness, and degeneration; thus, surgical reconstruction is the only option. To illustrate, total knee arthroplasty (TKA) is the replacement of the damaged parts of the knee with prosthetic components that are made of metal alloys, polyethylene, and ceramics to bring back the mobility while total hip arthroplasty (THA) due to severe hip OA or fractures is through using modular stems, acetabular cups, and femoral heads. One can learn from the American College of Rheumatology that approximately 790,000 total knee arthroplasties and 544,000 THA are carried out yearly in the US and also imbalances forecast an upward trajectory to 1.28 million knee replacements and 635,000 hip replacements by 2030 i.e. 189% and 171% increase correspondingly due to the rising disease burdens. Innovation is, by and large, what recent developments are reinforcing as a basis of progression in this sector. In effect, Zimmer Biomet gained FDA Breakthrough Device Designation, in October 2025, for the world's first iodine-treated total hip replacement system that is designed to lower the risk of infections via the release of antimicrobial properties while at the same time, promote osseointegration. Over the last 20 years, several improvements have been made to TKA, one of which is the near-universal practice of robotic-assisted surgery, which is more exact as it achieves implant alignment and lessens surgery-related complications by up to 20%. Simultaneously new biomaterials e.g. oxidized zirconium for wear-resistant surfaces and tailor-made (created via preoperative imaging) 3D-printed implants based on patient-specific are emerging to name a few. Coupled with augmented reality navigation systems, these innovations have contributed to shortening the recovery period as well as implant longevity to 20-25 years. The expansion of joint reconstruction is driven by various intertwined demographic and lifestyle factors. For instance, the aging population is primarily responsible for the amplified incidence of osteoarthritis (OA), as the process of cartilage degradation becomes significantly faster after the age of 50. One factor that contributes to the expansion is technological advancements such as minimally invasive surgeries and biologics integration e.g. use of stem cells as implant coatings that provide better outcomes and accessibility. In addition, early intervention promotion through public health initiatives and the removal of insurance barriers to coverage tantamount to demand sustaining. Together these elements have positioned the United States at the forefront of joint reconstruction where disease epidemiology meets state-of-the-art engineering resulting in a revolution in mobility for an increasingly arthritic population of old.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), American Association of Hip and Knee Surgeons (AAHKS), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the joint reconstruction devices market report.